Form D · Biotechnology
SENTI BIOSCIENCES, INC.
San Francisco, CA · CIK 0001732195
Offering snapshot reported Feb 26, 2018 · SEC filing
- Reported sold
- $39.4M Offering amount: $53.4M
- Investors reported
- 26 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 9, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 26, 2018 | Initial | $39,412,199 | No comparison | 26 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-306382
Source: Form D, filed Feb 26, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Alex Kolicich | Director |
| Philip Lee | Executive |
| Timothy Lu | Director, Executive |
| Ed Mathers | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
329 Oyster Point Blvd 3 Rd Fl
San Francisco, CA, 94080
San Francisco, CA, 94080